Drug‑Resistant Tuberculosis (DR‑TB)

Overview

Drug‑resistant tuberculosis (DR‑TB) refers to an infection caused by Mycobacterium tuberculosis strains that are not killed by the standard first‑line antibiotics (isoniazid and rifampin). The two most common forms are:

• Multidrug‑resistant TB (MDR‑TB): resistant to at least isoniazid (INH) + rifampin (RIF).
• Extensively drug‑resistant TB (XDR‑TB): MDR‑TB plus resistance to any fluoroquinolone and at least one of the three injectable second‑line drugs (amikacin, kanamycin, or capreomycin).

DR‑TB can affect anyone, but certain groups are disproportionately impacted:

• People living in high‑burden countries (India, China, Russia, South Africa, and the Philippines).
• Individuals with HIV/AIDS or other immunosuppressive conditions.
• Close contacts of a known DR‑TB case.
• Patients with a history of incomplete or irregular TB treatment.

According to the World Health Organization (WHO), in 2022 there were an estimated 500,000 new cases of rifampin‑resistant TB worldwide, of which 78% were MDR‑TB and 8% were XDR‑TB.^[1] In the United States, the CDC reports approximately 500–600 cases of MDR‑TB each year, a small fraction of total TB cases but a growing public‑health concern.^[2]

Symptoms

Symptoms of drug‑resistant TB are indistinguishable from drug‑sensitive TB. They usually develop weeks to months after infection and may be subtle at first.

Pulmonary (lung) symptoms

• Persistent cough lasting > 3 weeks, sometimes producing blood‑streaked sputum.
• Chest pain that worsens with deep breathing or coughing.
• Shortness of breath or wheezing, especially in advanced disease.
• Fatigue and weakness that do not improve with rest.

Systemic (general) symptoms

• Unexplained weight loss (often > 10 % of body weight).
• Night sweats – drenching sweating that soaks clothing or bedding.
• Fever – low‑grade, intermittent, often worse in the evening.
• Loss of appetite and reduced intake of food.

Extrapulmonary symptoms* (when TB spreads outside the lungs)

• Neck swelling or pain – indicates lymph node involvement (scrofula).
• Back pain or spinal deformity – suggests Pott disease (vertebral TB).
• Joint swelling or chronic arthritis.
• Abdominal pain, ascites, or intestinal obstruction.
• Neurological signs (headache, seizures, focal weakness) – meningeal TB.

*Extrapulmonary disease occurs in ~15‑20 % of TB cases and is more common among people with HIV or severe immunosuppression.

Causes and Risk Factors

Drug resistance arises when M. tuberculosis acquires genetic mutations that allow it to survive despite exposure to antibiotics. The mutations usually develop because of:

• Incorrect prescribing (e.g., wrong drug, wrong dose).
• Incomplete treatment courses – patients stop medication early due to side‑effects, lack of access, or misunderstanding.
• Irregular drug supply chains, especially in low‑resource settings.

Key risk factors

• Previous TB treatment – especially if it was irregular.
• HIV infection – weakens immunity and may hasten disease progression.
• Close contact with known DR‑TB case.
• Living or working in congregate settings (prisons, shelters, long‑term care facilities).
• Substance use – alcohol, tobacco, or illicit drugs can impair adherence.
• Diabetes mellitus – increases susceptibility to TB infection.
• Malnutrition or other conditions that compromise the immune system.

Diagnosis

Early and accurate diagnosis is essential because DR‑TB requires longer, more toxic, and costlier therapy than drug‑sensitive TB.

Initial evaluation

1. Medical history & physical exam – focus on TB exposure, prior treatment, HIV status, and symptom duration.
2. Chest radiography – may show cavitary lesions, infiltrates, or nodules.
3. Sputum microscopy (acid‑fast bacilli smear) – rapid but does not indicate resistance.

Microbiologic tests that determine resistance

• GeneXpert MTB/RIF (or Xpert Ultra) – a rapid molecular assay that detects M. tuberculosis DNA and rifampin resistance within 2 hours. Highly sensitive and recommended by WHO for initial screening.^[3]
• Line‑probe assays (LPAs) – detect mutations conferring resistance to isoniazid and rifampin and, in second‑line versions, fluoroquinolones and injectable drugs.
• Phenotypic drug‑susceptibility testing (DST) – culture the bacteria (solid or liquid media) and expose them to drugs to observe growth. Takes weeks but remains the gold standard for confirming resistance patterns.
• Whole‑genome sequencing (WGS) – increasingly used in reference labs; provides a complete resistance profile and can guide individualized regimens.

Additional investigations

• HIV testing – recommended for all TB patients.
• Baseline blood work (CBC, liver & renal function) before starting second‑line drugs.
• Electrocardiogram (ECG) – important if using fluoroquinolones or delamanid, which can prolong QT interval.
• Imaging for extrapulmonary disease – CT, MRI, or ultrasound as clinically indicated.

Treatment Options

DR‑TB treatment is complex, usually lasting 18‑24 months and involving multiple drugs with potentially serious side‑effects. Regimens are individualized based on DST results.

First‑line drugs (used only if susceptibility is confirmed)

• Isoniazid
• Rifampin
• Ethambutol
• Pyrazinamide

Second‑line oral agents (core of MDR‑TB regimens)

• Fluoroquinolones – levofloxacin or moxifloxacin (preferred for their potency).
• Injectable agents – amikacin, kanamycin, or capreomycin (used less frequently now because of ototoxicity).
• Novel oral drugs – bedaquiline, delamanid, pretomanid (approved by FDA & EMA for specific MDR/XDR‑TB regimens).
• Other oral agents – linezolid, clofazimine, ethionamide, cycloserine, and the newer agent, sulfamethoxazole‑trimethoprim, in selected cases.

Standardized WHO regimen (2023 update)

For most MDR‑TB patients without fluoroquinolone resistance, WHO recommends a 6‑month intensive phase (bedaquiline + fluoroquinolone + linezolid + clofazimine + pyrazinamide) followed by a 12‑month continuation phase (bedaquiline + fluoroquinolone + linezolid + clofazimine). Doses are weight‑based and closely monitored for toxicity.

Adjunctive measures

• Directly observed therapy (DOT) – ensures medication adherence.
• Nutritional support – high‑calorie, protein‑rich diets improve outcomes.
• Management of comorbidities – HIV antiretroviral therapy, diabetes control.
• Surgical intervention – limited to patients with massive cavitary disease, persistent hemoptysis, or drug‑resistant disease not responding to medication.

Side‑effect monitoring

Patients should be educated about common adverse events:

• Hepatotoxicity (elevated liver enzymes) – monitor monthly.
• QT prolongation – baseline & monthly ECGs when using bedaquiline, delamanid, or moxifloxacin.
• Peripheral neuropathy (linezolid) – assess for tingling, weakness.
• Hearing loss (injectables) – audiogram if injectable is used.
• Depression or mood changes (some second‑line agents).

Living with Drug‑Resistant Tuberculosis

Managing DR‑TB is a daily commitment for patients and families. Below are practical tips to improve adherence, reduce transmission, and maintain quality of life.

Medication adherence

• Use a pill organizer or a smartphone reminder app.
• Attend all DOT appointments; if not feasible, arrange video‑observed therapy.
• Keep a medication diary noting dose, time, and any side‑effects.

Nutrition & hydration

• Consume at least 2 500 kcal/day for adult men and 2 000 kcal/day for adult women, plus extra protein (1.5 g/kg body weight).
• Include vitamin‑rich foods (fruits, leafy greens) to support immunity.
• Stay hydrated – aim for 2–3 L of fluid daily unless contraindicated.

Infection control at home

• Sleep in a well‑ventilated room; keep windows open if weather permits.
• Wear a surgical mask when coughing around others; change it daily.
• Cover mouth and nose with a tissue when coughing, dispose of it immediately.
• Limit close contact with infants, pregnant women, and immunocompromised individuals.

Emotional & psychosocial support

• Join a support group for TB patients—many hospitals and NGOs run virtual meetings.
• Seek counseling if you experience anxiety, depression, or stigma.
• Inform close contacts about the disease; transparency reduces fear and promotes cooperation.

Follow‑up care

• Schedule monthly clinic visits for lab tests, drug‑level checks, and symptom review.
• Report any new symptoms promptly—especially visual changes, hearing loss, or severe gastrointestinal upset.
• Keep a record of all test results and share them with every healthcare provider involved in your care.

Prevention

Preventing DR‑TB focuses on both preventing TB infection and preventing the development of resistance.

Primary prevention (avoid infection)

• BCG vaccination – provides protection against severe childhood TB; effectiveness against pulmonary TB varies.
• Screening of high‑risk groups – regular chest X‑ray and sputum testing for contacts of TB cases, persons living with HIV, and healthcare workers.
• Environmental controls – adequate ventilation in congregate settings, use of ultraviolet germicidal irradiation (UVGI) where feasible.

Secondary prevention (prevent resistance)

• Ensure **complete, directly observed therapy** for all drug‑sensitive TB cases.
• Use **fixed‑dose combination (FDC) pills** to reduce the chance of missing a drug.
• Provide **patient education** on side‑effects and the importance of not stopping medication early.
• Strengthen **drug supply chains** so that interruptions do not occur.

Vaccines in development

Several novel TB vaccines (e.g., M72/AS01E, VPM1002) are in phase III trials and may, in the future, reduce both TB incidence and drug‑resistance rates.^[4]

Complications

If DR‑TB is not treated adequately, the infection can cause serious, sometimes fatal, complications.

• Respiratory failure due to massive cavitation, fibrosis, or pneumothorax.
• Hemoptysis (coughing up blood) from erosion of blood vessels in cavities.
• Spread to other organs – meningitis, pericarditis, genitourinary TB, or bone/joint disease.
• Drug toxicity – cumulative liver injury, renal failure, or severe ototoxicity.
• Increased HIV progression – uncontrolled TB drives HIV viral replication.
• Social and economic impact – prolonged inability to work, stigma, and mental‑health disorders.

When to Seek Emergency Care

References

1. World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023. Link
2. Centers for Disease Control and Prevention. Drug‑Resistant Tuberculosis (TB). Updated 2024. Link
3. CDC. Drug‑Resistant Tuberculosis: Overview. 2024. Link
4. Abubakar I, et al. “Vaccine Development for Tuberculosis: Progress and Challenges.” Nature Reviews Immunology. 2021;21:594‑609. PMCID
5. Mayo Clinic. Tuberculosis (TB) – Symptoms, Causes, Treatments. 2024. Link